BI 224436
![]() | |
Clinical data | |
---|---|
ATC code | none |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Biological half-life | 7 hrs (simulated)[1] |
Identifiers | |
| |
ChemSpider | 27289461 |
Chemical and physical data | |
Formula | C24H25NO4 |
Molar mass | 391.460 g/mol |
3D model (Jmol) | Interactive image |
| |
|
BI 224436 is an investigational new drug under development for the treatment of HIV infection. BI 224436 is the first non-catalytic site integrase inhibitor (NCINI). It inhibits HIV replication via binding to a conserved allosteric pocket of the HIV integrase enzyme. This makes the drug distinct in mechanism of action compared to raltegravir and elvitegravir, which bind at the catalytic site.[2] In October 2011, Gilead Sciences purchased exclusive rights to develop BI 224436 and several related compounds under investigation in Boehringer Ingelheim’s noncatalytic site integrase inhibitor program.[3][4]
References
- ↑ Pharmacodynamics of BI 224436 for HIV-1 in an in vitro hollow fiber infection model system
- ↑ Levin, Jules. BI 224436, a Non-Catalytic Site Integrase Inhibitor, is a potent inhibitor of the replication of treatment-naïve and raltegravir-resistant clinical isolates of HIV-1. Conference Reports for NATAP. ICAAC Chicago Sept 17-20 2011.
- ↑ Gilead Negotiates Worldwide License to BI’s Early Clinical Stage HIV Program. Genetic Engineering and Biotechnology News. 6 Oct 2011.
- ↑ Highleyman, Liz. ICAAC: New Integrase Inhibitor BI 224436 Active against Raltegravir-Resistant HIV. HIVandHepatitis.com. 7 Oct 2011.
This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.